Abivax reported robust phase 3 data for obefazimod in ulcerative colitis, linking the oral small molecule to placebo-adjusted clinical remission rates of 39.3% and 40.3% at Week 44 for its 25 mg and 50 mg doses. That compares with 10.4% remission on placebo, placing obefazimod ahead of AbbVie’s Rinvoq (39%) and Pfizer’s Velsipity (32%) in comparable maintenance studies. Yet the stock still sank after several patients on the 50 mg dose developed cancers. Infection rates stayed in line with placebo, and discontinuations were actually lower on active drug. Abivax, often floated as an $18 billion acquisition target for AstraZeneca or Eli Lilly, has signaled it will hold off on partnership talks outside the U.S. until 48‑week data are in.
This outcome leaves Abivax with a split story: outstanding efficacy numbers, shadowed by a potential safety concern. On paper, obefazimod delivers the first oral anti‑inflammatory to match JAK inhibitors without boxed warnings. But the cancer signal, rare as it is, punctures that narrative. It forces investors to weigh whether regulators will impose extended surveillance or post‑marketing commitments, any of which would dent the near‑term takeover trade. The tension is palpable on trading desks; one portfolio manager told me the market “doesn’t forgive uncertainty in inflammation drugs.” Fair point.
Whether those malignancies are incidental or something deeper remains open. If they’re unlucky coincidences, pharma strategists could still view Abivax as one of the last high‑efficacy oral assets left to grab in ulcerative colitis, particularly for refractory patients that define the category’s next growth leg. If not, if causality sticks, then the $18 billion rumor fades fast. For now, watch the 48‑week update and any movement from the FDA or EMA. And for commercial teams benchmarking oral IBD therapies, RxInfo.ai is still the place to start. Then again, after this data cycle, everyone’s watching Abivax anyway.
